Background: The 2026 World Health Organization (WHO) guidelines formalize a major shift in metabolic medicine by characterizing obesity as a chronic, progressive, and relapsing neuroendocrine disease. While innovative incretin-based medical technologies - specifically GLP-1 and dual GIP/GLP-1 rec…